The fluctuation of the function of the adrenal gland, both cortex and medulla, after treatment was observed in diabetics admitted to our Department.
The average content of 17-OHCS in plasma was within the normal range before treatment and was not changed after treatment in type I diabetics, while it was higher than the normal range before treatment and decreased after treament in type II diabetics.
The average excretions of urinary 17-OHCS before therapy were 7.9 and 10.0 mg. daily in type I and type II diabetics, respectively, whereas after therapy they were 8.1 and 5.2 mg. per day in type I and type II diabetics, respectively. A decreased excretion of urinary 17-OHCS was found especially in type II diabetics when well controlled.
The average excretion of 17-KS in urine was within the normal range before treatment in both types of diabetics. Higher value of urinary excretion of 17-KS was observed in 10 per cent out of thirty type I diabetics and 35 per cent out of fifty-four type II diabetics. After treatment, the average urinary excretions of 17-KS were 7.7 and 7.4 mg. per day, respectively.
The average excretion of uropepsin in type I diabetics before treatment was 273 micrograms per hour, decreasing to 218 micrograms after treatment. It was 388 micrograms in type II diabetics before treatment and markedly decreased to 261 micrograms after therapy.
The eosinophil cells in blood were within the normal range and were markedly reduced in five out of thirty-one type I diabetics and twelve out of thirty type II diabetics before treatment. They decreased only in one out of seven type I and three out of ten type II diabetics after treatment.
The response of eosinophil cells to the administration of ACTH-Z was within the normal range in both diabetic types before and after treatment.
The urinary excretion of adrenaline in diabetics was significantly decreased as compared with the normal subjects. The mean values were 5.5 and 4.7 micrograms daily in type I and type II diabetics, respectively. They remained to be low after treatment, 6.2 and 4.3 micrograms per day in type I and type II diabetics, respectively.
The mean values of urinary noradrenaline excretion in diabetics remained within the normal range before treatment and they did not fluctuate after therapy.
The hyperfunction of the adrenal cortex and a decreased excretion of urinary adrenaline in diabetics were discussed.
View full abstract